Immunomedics Inc. (IMMU)

Oncology Corporate Profile

Stock Performance

3.6900
0.3600

HQ Location

300 American Road
Morris Plains, NJ 7950

Company Description

Immunomedics is committed to be a leading, innovative biopharmaceutical company, dedicated to improving health and quality of life with novel immunotherapeutics for the treatment of cancer, autoimmune and other serious diseases.

Website: http://www.immunomedics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
epratuzumabanti-CD22 monoclonal antibodyAcute Lymphocytic Leukemia (ALL)II
sacituzumab govitecan / IMMU-132antibody drug conjugateBreast cancerII
IMMU-130antibody drug conjugateColorectal cancerII
sacituzumab govitecan / IMMU-132antibody drug conjugateColorectal cancerII
labetuzumabanti-CEA monoclonal antibody (humanized)Colorectal cancerII
epratuzumabanti-CD22 monoclonal antibodyDiffuse large B-cell Lymphoma (DLBCL)II
sacituzumab govitecan / IMMU-132antibody drug conjugateGastric cancerII
sacituzumab govitecan / IMMU-132antibody drug conjugateNon Small Cell Lung Cancer (NSCLC)II
epratuzumabanti-CD22 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)II
milatuzumabanti-CD74 monoclonal antibodyChronic Lymphocytic Leukemia (CLL)I
veltuzumab / IMMU-106anti-CD20 monoclonal antibodyChronic Lymphocytic Leukemia (CLL)I
IMMU-114anti-CD20 monoclonal antibodyChronic Lymphocytic Leukemia (CLL)I
clivatuzumab tetraxetanmonoclonal antibody targeting mucin antigen (humanizedInoperable 2nd line metastatic Pancreatic cancerI
milatuzumabanti-CD74 monoclonal antibodyMultiple MyelomaI
milatuzumabanti-CD74 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)I
veltuzumab / IMMU-106anti-CD20 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)I
IMMU-114anti-CD20 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)I
Y-hPAM4yttrium-labeled antibodyPancreatic cancerI

View additional information on product candidates here »

Pipeline image

Source


http://www.immunomedics.com

Recent News Headlines

Immunomedics Shares Plunge After Finance Chief Steps Down

6/23/2016 11:34 am

(Bloomberg) June 21, 2016 - CFO Peter Pfreundschuh will be replaced by Michael Garone; stock has fallen steadily since ASCO presentation pulled.

Immunomedics Announces Sacituzumab Govitecan (IMMU-132) is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer

6/6/2016 05:30 pm

(Immunomedics) June 6, 2016 - Immunomedics, Inc., today reported an overall response rate of 24% (8/33) in assessable patients with metastatic small-cell lung cancer (SCLC) after receiving treatment with sacituzumab govitecan, its lead investigational antibodydrug conjugate (ADC), at the dose level of 8 mg/kg or 10 mg/kg.

Immunomedics' Sacituzumab Govitecan (IMMU-132) Demonstrates Efficacy and Safety in Non-Small-Cell Lung Cancer Patients With Multiple Prior Treatments, Including Immuno-Oncology

6/6/2016 05:30 pm

(Yahoo! Finance) June 6, 2016 - Immunomedics, Inc., today announced that sacituzumab govitecan (IMMU-132), its lead investigational antibody-drug conjugate (ADC), shrank tumors by 30% or more initially in 26% (12/46) of evaluable patients with metastatic non-small-cell lung cancer (NSCLC), with a later confirmed overall objective response rate (ORR) of 13%, in accordance with RECIST 1.1 criteria.

Immunomedics Provides Update on Triple-Negative Breast Cancer Presentation at ASCO

6/3/2016 01:14 pm

(StreetInsider) June 3, 2016 - Immunomedics, Inc., today announced that the Company was advised late yesterday that its abstract, “Therapy of refractory/relapsed metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results,” planned for oral presentation today and selected by the American Society of Clinical Oncology (ASCO) for its Press Briefing, was cancelled because of a complaint that the Company violated the embargo by reporting results presented by its Chairman at a conference in April.

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

6/3/2016 06:22 am

(TheStreet.com) June 2, 2016 - Immunomedics was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting.

Immunomedics to Report Updated Results for Sacituzumab Govitecan (IMMU-132) in Breast and Lung Cancers at Clinical Science Symposia of 2016 ASCO Annual Meeting

5/19/2016 12:32 pm

(Yahoo! Finance) May 19, 2016 - Immunomedics, Inc., today announced that the Scientific Program Committee of the American Society of Clinical Oncology (ASCO) has selected two of the Company’s abstracts for oral presentation at two Clinical Science Symposium Sessions during their 2016 Annual Meeting, scheduled for June 3-7, 2016 at McCormick Place Convention Center in Chicago, Illinois.

Immunomedics Reports Responses With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Solid Cancers Who Failed Prior Checkpoint-Inhibitor Therapy

5/2/2016 11:12 am

(Yahoo! Finance) Apr 29, 2016 - Immunomedics, Inc. today announced that objective durable responses have been achieved with sacituzumab govitecan, its lead antibody-drug conjugate (ADC), in a number of patients with advanced, metastatic solid cancers, after failing multiple prior therapies, some including checkpoint inhibitors (CPIs).

U.S. FDA Lifts Partial Clinical Hold on Medivation's Pidilizumab

3/9/2016 12:05 pm

(NASDAQ) Mar 9, 2016 - Potentially pivotal phase II trial in DLBCL and other studies may proceed.

Deadline for New Survey on Practice Operations Extended to February 22

2/17/2016 12:01 pm

(ASCO in Action) Feb 12, 2016 - ASCO’s Clinical Affairs department has extended the deadline on the new annual survey, the 2016 Survey of Oncology Practice Operations (SOPO), which seeks feedback on practice management.

CardioBrief: FDA Turns Down Expanded Indication for Ezetimibe

2/17/2016 12:01 pm

(MedPage Today) Feb 16, 2016 - The FDA has turned down Merck's application to expand the indication for its cholesterol-lowering drug ezetimibe, either by itself (Zetia) or in combination with simvastatin (Vytorin). This means there's still no end in sight for this drug's very long and very winding road.

U.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Immunomedics for Sacituzumab Govitecan for the Treatment of Patients With Triple-Negative Breast Cancer

2/5/2016 12:09 pm

(NASDAQ) Feb 5, 2016 - Immunomedics, Inc., today announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease.

Biden to Bring Cancer Tour to Duke

2/5/2016 12:01 pm

(The News & Observer/Under the Dome blog [Raleigh, NC]) Feb 5, 2016 - Vice President Joe Biden will be at Duke University on Wednesday as part of the “National Cancer Moonshot” initiative that President Barack Obama tapped him to run during his State of the Union address last month.

Three Industry Leaders Join the CancerLinQ™ Team to Help Guide Big-Data Initiative

2/5/2016 12:01 pm

(ASCO) Feb 4, 2016 - CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology, has named three new members to its leadership team.

Immunomedics Reports Continuing Positive Results With Sacituzumab Govitecan in Heavily Pre-Treated Metastatic Triple-Negative Breast Cancer Patients

12/10/2015 12:03 pm

(Yahoo! Finance) Dec 10, 2015 - Immunomedics, Inc. today announced updated results from a Phase 2 clinical study of sacituzumab govitecan, its lead investigational antibody-drug conjugate (ADC), in patients with metastatic triple-negative breast cancer (mTNBC) who had received a median of 5 (range, 2 -- 12) prior lines of therapy.

ASCO Releases Principles for Developing a Sustainable Medicare Payment System for Clinical Oncology

11/19/2015 12:02 pm

(ASCO) Nov 18, 2015 - Society's response to RFI on MACRA focuses on protecting interests of Medicare beneficiaries with cancer.

Cancer Meds Often Bring Big Out-Of-Pocket Costs For Patients, Report Finds

11/19/2015 12:02 pm

(KHN) Nov 19, 2015 - Cancer patients shopping on federal and state insurance marketplaces often find it difficult to determine whether their drugs are covered and how much they will pay for them, the advocacy arm of the American Cancer Society says in a report that also calls on regulators to restrict how much insurers can charge patients for medications.

MRI Could Detect Head and Neck Cancer's Resistant Cores

11/19/2015 12:01 pm

(ICR [UK]) Nov 17, 2015 - Grouping magnetic resonance imaging data into clusters could detect treatment-resistant cores inside head and neck tumours, a new study shows.

Baby's Experimental Leukemia Treatment Could Help Others with Cancer

11/19/2015 12:01 pm

(Scientific American/Live Science) Nov 18, 2015 - A gene-editing technology that made headlines recently for successfully treating a baby with leukemia may one day be used to treat other types of cancers, experts say.

Companion Diagnostics? For Cancer Care, We Need Better Ones

11/19/2015 12:01 pm

(Forbes) Nov 19, 2015 - Maybe it takes a certain set of experiences like going to medical school and then having cancer, or geekiness, to get excited by spending two days at a biotech conference on companion diagnostics, CDx.

New Study Suggests More Than 8 Percent Of Children With Cancer Have Genetic Predisposition

11/19/2015 12:00 pm

(St. Jude Children's) Nov 18, 2015 - St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project completes the most comprehensive analysis yet of the role genes associated with cancer predisposition play in childhood cancer.

Anti-PD-1 Agents Superior to Others in Advanced Melanoma

11/19/2015 12:00 pm

(Medscape Medical News) Nov 19, 2015 - Immunotherapy targeting the programmed cell death (PD) pathway was associated with better outcomes in patients with metastatic melanoma than any other therapy, a new meta-analysis concludes.

Super-Responder Buzzkill: Some Likely Have Indolent Cancers

11/19/2015 12:00 pm

(Medscape Medical News) Nov 19, 2015 - Some super-responders to specific cancer treatments likely have slow-growing tumors or cancers that are broadly sensitive to oncologic therapy, according to a first-of-its kind study.

Pigeons Good at Detecting Breast Cancer

11/19/2015 12:00 pm

(Discovery News) Nov 18, 2015 - Although pigeons have brains that are no bigger than the tip of an index finger, several in a recent study were able to distinguish digitized microscope slides and mammograms of normal versus cancerous breast tissue.

Working up a Sweat May Protect Against Lethal Prostate Cancer

11/19/2015 12:00 pm

(University of California) Nov 17, 2015 - A study that tracked tens of thousands of midlife and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may cut their chances of developing a lethal type of prostate cancer by up to 68 percent.

Telesta Therapeutics Announces Results of the FDA Advisory Committee Vote

11/19/2015 06:05 am

(Telesta Therapeutics) Nov 19, 2015 - Telesta Therapeutics Inc. today announced the results of the US Food and Drug Administration’s (FDA) Joint Meeting of the Cellular, Tissue and Gene Therapies Advisory Committee and Oncologic Drugs Advisory Committee (“Advisory Committee”) held on November 18, 2015 to discuss the safety and efficacy of Telesta’s Biologics License Application (BLA) for MCNA.

Study Could Result in New Strategies For Treating Juvenile Cancer

11/19/2015 06:05 am

(Wall Street Journal) Nov 18, 2015 - A detailed analysis of the DNA of more than 1,100 children is shedding light on one of medicine’s most perplexing mysteries: Why do kids get cancer?

Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial

11/19/2015 06:04 am

(Lilly) Nov 19, 2015 - Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA® (pemetrexed for injection) and Merck's KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

CURE Media Group and IHadCancer.com Partner to Advance Cancer Education and Support Patients

11/18/2015 12:05 pm

(PRWEB) Nov 18, 2015 - Patient-focused media group and leading web-based cancer support organization join forces to help those affected by cancer.

IMS Health: Drug Spending to Jump 30 Pct. To $1.3T in 2020

11/18/2015 12:01 pm

(New York Times/Associated Press) Nov 18, 2015 - As criticism of soaring prescription drug prices in the U.S. grows, global spending on medicines is expected to rise 3 percent to 6 percent annually for the next five years, according to a new forecast from IMS Health.

Immunomedics Reports Improved Progression-Free Survival Results With Sacituzumab Govitecan in Triple-Negative Breast Cancer

11/9/2015 10:46 am

(StreetInsider) Nov 9, 2015 - Immunomedics, Inc. today announced that patients with metastatic triple-negative breast cancer (TNBC) lived for a median of seven months without tumor progression, after receiving at least 3 doses of sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC) for solid cancer therapy, in a Phase 2 clinical study.

Amgen And University Of California, Berkeley Announce Multi-Year Partnership To Assist Cancer Patient Advocacy Organizations In Measuring Effectiveness Of Programs

8/18/2015 12:01 pm

(MarketWatch) Aug 18, 2015 - Amgen and the Center for Social Sector Leadership at the University of California (UC), Berkeley's Haas School of Business today announced a multi-year partnership to offer a graduate-level course on measuring outcomes of cancer patient advocacy education and support programs.

Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Immune Thrombocytopenia

8/4/2015 11:32 am

(StreetInsider) Aug 4, 2015 - Immunomedics, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted orphan status for the use of veltuzumab, the Company's humanized anti-CD20 antibody, for the treatment of immune thrombocytopenia (ITP).

ASCO Urges Expansion of Cancer Research to Include More Older Adults

7/21/2015 11:04 am

(ASCO) July 20, 2015 - The American Society of Clinical Oncology (ASCO) today issued landmark recommendations calling for federal agencies and the cancer research community to broaden clinical trials to include older adults. ASCO also called for redefining eligibility for clinical trials. Both calls to action were published in the Journal of Clinical Oncology.

Immunomedics Reports Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer

6/2/2015 04:51 pm

(TheStreet) June 2, 2015 - Immunomedics, Inc., today announced an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate (ADC), labetuzumab govitecan, produced encouraging survival results in patients previously treated with at least one prior irinotecan-containing regimen for their metastatic colorectal cancer (mCRC).

Immunomedics Announces Durable Responses in Metastatic Lung Cancer Patients Treated with Sacituzumab Govitecan

6/2/2015 04:51 pm

(Yahoo! Finance) June 2, 2015 - Immunomedics, Inc., today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), demonstrated in a mid-stage clinical study promising anti-tumor activity in patients with metastatic lung cancer.

Immunomedics Reports Complete Responses in Patients with Metastatic Triple-Negative Breast Cancer After Sacituzumab Govitecan Treatment

6/1/2015 06:15 pm

(Yahoo! Finance) June 1, 2015 - Immunomedics, Inc., today announced that among 49 patients with metastatic triple-negative breast cancer (TNBC) evaluated for response to treatments with sacituzumab govitecan in a mid-stage clinical study, 31%, or 15 patients, showed a reduction in tumor size of 30% or more.

Immunomedics Awarded Fast Track Designation By FDA For Sacituzumab Govitecan For Non-Small Cell Lung Cancer Therapy

5/18/2015 01:12 pm

(TheStreet) May 15, 2015 - Immunomedics, Inc., today announced that it has received notice from the FDA designating as a Fast Track development program sacituzumab govitecan, the Company's lead antibody-drug conjugate (ADC), for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).

'Personalised' Cancer Vaccine Moves a Step Closer

4/23/2015 12:02 pm

(The Independent [UK]) Apr 22, 2015 - A cancer vaccine that is tailor-made to work on individual patients has come a step closer following a study showing that a prototype injection causes the complete control of aggressive tumours in laboratory mice.

Use of New Systemic Adjuvant Therapy in Gastrointestinal Tumors (GISTs) Increasing, Leading to Better Survival

3/2/2015 11:05 am

(ACS) Mar 2, 2015 - A new American Cancer Society study finds that the use of adjuvant systemic therapy for localized gastrointestinal stromal tumors (GISTs ) has significantly increased over time and that patients treated with the therapy have better survival than those treated with surgery alone.

Immunomedics Presents Updated Results With Sacituzumab Govitecan in Lung Cancer

2/20/2015 10:59 am

(CNNMoney) Feb 19, 2015 - Immunomedics, Inc. today announced that 33% of patients with small cell lung cancer and 31% with non-small cell lung cancer had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC).

Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers

1/22/2015 11:22 am

(Immunomedics) Jan 20, 2015 - Immunomedics, Inc., today announced that sacituzumab govitecan, the Company’s lead investigational antibody-drug conjugate (ADC), produces partial response (PR) in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated.

Hospira Submits New Biologics License Application Biosimilar Retacrit

1/14/2015 12:03 pm

(RTTNews.com) Jan 12, 2015 - Hospira, Inc., a provider of injectable drugs and infusion technologies, Monday announced the submission of a Biologics License Application or BLA to the U.S. Food and Drug Administration for Retacrit.